CN109628417A - 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 - Google Patents
鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 Download PDFInfo
- Publication number
- CN109628417A CN109628417A CN201811600142.6A CN201811600142A CN109628417A CN 109628417 A CN109628417 A CN 109628417A CN 201811600142 A CN201811600142 A CN 201811600142A CN 109628417 A CN109628417 A CN 109628417A
- Authority
- CN
- China
- Prior art keywords
- gene
- bac
- dpv
- pbac
- kana
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001492342 Anatid alphaherpesvirus 1 Species 0.000 title claims abstract description 51
- 238000010276 construction Methods 0.000 title claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 239000013612 plasmid Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims description 21
- 238000012408 PCR amplification Methods 0.000 claims description 16
- 238000004925 denaturation Methods 0.000 claims description 16
- 230000036425 denaturation Effects 0.000 claims description 16
- 238000011144 upstream manufacturing Methods 0.000 claims description 15
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 238000000137 annealing Methods 0.000 claims description 8
- 239000012154 double-distilled water Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 240000000220 Panda oleosa Species 0.000 claims description 4
- 235000016496 Panda oleosa Nutrition 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 20
- 101150030521 gI gene Proteins 0.000 abstract description 12
- 210000004436 artificial bacterial chromosome Anatomy 0.000 abstract description 10
- 230000006801 homologous recombination Effects 0.000 abstract description 8
- 238000002744 homologous recombination Methods 0.000 abstract description 8
- 230000006798 recombination Effects 0.000 abstract description 6
- 238000005215 recombination Methods 0.000 abstract description 6
- 101150072564 gE gene Proteins 0.000 abstract description 5
- 206010035148 Plague Diseases 0.000 abstract description 4
- 241000607479 Yersinia pestis Species 0.000 abstract description 4
- 230000002238 attenuated effect Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 abstract description 3
- 229960005486 vaccine Drugs 0.000 abstract description 3
- 238000012217 deletion Methods 0.000 abstract description 2
- 230000037430 deletion Effects 0.000 abstract description 2
- 241000272865 Oxyura vittata Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 34
- 239000007788 liquid Substances 0.000 description 31
- 229960005091 chloramphenicol Drugs 0.000 description 27
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 241000272525 Anas platyrhynchos Species 0.000 description 13
- 238000001816 cooling Methods 0.000 description 12
- 230000005611 electricity Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000710778 Pestivirus Species 0.000 description 3
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011022 operating instruction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 description 1
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241001051756 Mardivirus Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种鸭瘟病毒gE和gI双基因无痕缺失株CHv‑BAC‑G‑ΔgE+ΔgI及其构建方法。本发明利用GS1783大肠杆菌菌株及pEPkan‑S质粒,在细菌人工染色体重组鸭瘟病毒拯救系统平台上经两次同源重组缺失鸭瘟病毒gE基因和gI基因,首次完成了无外源碱基残留的鸭瘟病毒双基因无痕缺失株的构建。本发明技术方案解决了缺失鸭瘟病毒基因时在缺失位点残留碱基的问题,为准确探究鸭瘟病毒基因功能及减毒活疫苗的构建提供了充分的技术支持。
Description
技术领域
本发明属于基因工程技术领域,具体涉及一种鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法。
背景技术
细菌人工染色体(bacterial artificial chromosome,BAC)是一种新发展起来的DNA载体系统,它具有容量大、遗传特性稳定、易于操作等优点,在基因文库构建和基因功能分析等方面有广泛的应用。将完整病毒基因组DNA分子插入BAC载体,利用该载体编码的最小生育力因子复制子(Minimal fertility factor replicon,Mini-F)获得分子克隆化病毒,并结合大肠杆菌中成熟的基因定位修饰技术,从而实现在原核系统中病毒基因的缺失及外源基因的插入。目前较为常用的大肠杆菌基因定位修饰技术主要包括Red/ET介导的同源重组技术、RecA蛋白介导的同源重组技术、Cre/loxP介导的同源重组技术以及Tn转座子介导的随机插入和突变技术。利用分子克隆化技术手段现已获得成熟的细菌人工染色体鸭瘟病毒拯救系统平台,同时利用大肠杆菌基因定位修饰Red/ET介导的同源重组技术可在细菌人工染色体鸭瘟病毒拯救系统平台上进行鸭瘟病毒基因的缺失和外源基因的插入,该成果极大的推动了鸭瘟病毒基因功能的研究进程。
Red/ET介导的同源重组技术是基于λ-噬菌体Red操纵子(Redα/Redβ/Redγ)和Rac噬菌体RecE/RecT同源重组酶的同源重组打靶技术。该技术操作简单、快速、高效,广泛应用于基因缺失、突变工作。但是利用该操作技术进行基因缺失、突变会在缺失或突变位点残留约80bp左右外源碱基序列(FRT位点),该位点的残留将影响基因功能的准确分析。
鸭瘟(Duck Plague,DP)是由α-疱疹病毒亚科中鸭瘟病毒(Duck Plague virus,DPV)引起的鸭、鹅等水禽的急性接触性高度致死性传染病。该病首先由荷兰报道,随即在我国华南、华中和华东等养鸭业较为发达的地区流行,给我国的养鸭业造成了严重的经济损失。因此深入了解鸭瘟病毒基因功能、加强对鸭瘟疫病的研究对确保我国养鸭业健康、可持续发展尤为重要。
鸭瘟病毒DPV-CHv株基因组DNA全长162175bp,包含78个开放阅读框,可编码参与鸭瘟病毒生命周期的结构蛋白和非结构蛋白,其中结构蛋白主要包括衣壳蛋白、皮层蛋白和囊膜蛋白。囊膜蛋白为糖基化蛋白,包括gB、gC、gD、gE、gG、gH、gI、gJ、gK、gL、gM、gN十二种。糖蛋白具有介导病毒吸附、进入敏感细胞以及促进病毒在细胞间传播的功能,同时携带抗原决定簇,可诱导动物机体免疫系统对病毒的识别并造成组织的病理损伤,因此探究囊膜糖蛋白在鸭瘟病毒生命周期中的作用对深入探究鸭瘟病毒基因功能及开展鸭瘟疫病防治工作至关重要。
现有技术中利用以BAC为平台分子克隆化病毒的技术,将鸭瘟病毒基因组重组到含有BAC的病毒转移载体中,构建细菌人工染色体重组鸭瘟病毒拯救系统平台DPV CHv-BAC-G。同时结合Red/ET修饰技术,在原核系统中通过成熟的基因操作手段完成鸭瘟病毒基因缺失和外源基因插入。但利用Red/ET修饰技术在细菌人工染色体重组鸭瘟病毒拯救系统平台上对鸭瘟病毒基因缺失后,会在缺失基因处残余两处FRT位点。FRT外源位点的残留对基因功能的探究、减毒活疫苗的开发和许可存在影响。
发明内容
针对现有技术中存在的上述问题,本发明提供一种鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法,该构建方法可有效解决缺失鸭瘟病毒基因时在缺失位点残留碱基的问题。
为实现上述目的,本发明解决其技术问题所采用的技术方案是:
一种鸭瘟病毒gE和gI双基因无痕缺失株,为马立克病毒属Mardivirus,命名为鸭瘟病毒gE和gI双缺失病毒株CHv-BAC-G-ΔgE+ΔgI,于2018年7月4日保藏于中国典型培养物保藏中心(地址为:湖北省武汉市武昌区武汉大学),保藏编号为CCTCC NO:V201827。
上述鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI(即鸭瘟病毒gE和gI双缺失病毒株CHv-BAC-G-ΔgE+ΔgI)的构建方法包括以下步骤:
(1)将pBAC-DPV质粒转化到GS1783大肠杆菌感受态中,获得GS1783-pBAC-DPV菌株,然后制备GS1783-pBAC-DPV感受态;
(2)以pEPkan-S为模板,以GS1783-BAC-ΔgE-F和GS1783-BAC-ΔgE-R作为引物,通过PCR方法扩增包含I_SceI酶切位点和Kana元件的碱基片段以及gE基因上游和下游各40bp同源臂的打靶片段I_SceI-Kana-gE,切胶回收获得I_SceI-Kana-gE片段;
(3)将I_SceI-Kana-gE片段转化到GS1783-pBAC-DPV感受态中,筛选,获得阳性克隆子GS1783-pBAC-DPV-gE-Kana;
(4)将阳性克隆子GS1783-pBAC-DPV-gE-Kana中的I_SceI-Kana片段去掉,制备GS1783-pBAC-DPV-ΔgE感受态;
(5)以pEPkan-S为模板,以GS1783-BAC-ΔgI-F和GS1783-BAC-ΔgI-R作为引物,通过PCR方法扩增包含I_SceI酶切位点和Kana元件的碱基片段以及gI基因上游和下游各40bp同源臂的打靶片段I_SceI-Kana-gI,切胶回收获得I_SceI-Kana-gI片段;
(6)将I_SceI-Kana-gI片段转化到GS1783-pBAC-DPV-ΔgE感受态中,经抗生素筛选和PCR鉴定,获得阳性克隆子GS1783-pBAC-DPV-ΔgE-gI-Kana;
(7)将阳性克隆子GS1783-pBAC-DPV-ΔgE-gI-Kana中的I_SceI-Kana片段去掉,制备阳性克隆子GS1783-pBAC-DPV-ΔgE+ΔgI;
(8)从阳性克隆子GS1783-pBAC-DPV-ΔgE+ΔgI中提取pBAC-DPV-ΔgE+ΔgI质粒,将pBAC-DPV-ΔgE+ΔgI质粒转染DEF细胞,通过克隆筛选,获得gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI。
进一步地,步骤(2)和步骤(5)中PCR扩增体系为:ddH2O 22μl、MaxDNA Polymerase 25μl、上游引物1μl、下游引物1μl、模板1μl;PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min。
进一步地,步骤(2)中引物序列为:
GS1783-BAC-ΔgE-F:5’-ATACTGCCGGCCAGACTACGGAACCTCAACAATTGGTACGtagggataacagggtaatcgattt-3’;
GS1783-BAC-ΔgE-R:5’-TAACTATTTCACTAGTGAGTCATTAGTTCAACATCCATGACGTACCAATTGTTGAGGTTCCGTAGTCTGGCCGGCAGTATgccagtgttacaaccaat-3’。
进一步地,步骤(5)中引物序列为:
GS1783-BAC-ΔgI-F:5’-GTGCGCCATATAGACGATATATTGAGTTTCAAAAATAGAAtagggataacagggtaatcgattt-3’;
GS1783-BAC-ΔgI-R:5’-TCATAACAAAAACATTTACTTTTAGTCATACTGATGTGAATTCTATTTTTGAAACTCAATATATCGTCTATATGGCGCACgccagtgttacaaccaat-3’。
本发明提供的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法,具有以下有益效果:
为获得无外源碱基残留的鸭瘟病毒基因缺失株,本发明在细菌人工染色体重组鸭瘟病毒拯救系统平台的基础上,利用Red-based修饰技术,即利用含有可编码Red操纵子和I_SceI酶基因序列的GS1783大肠杆菌菌株及含有编码卡纳抗性及I_SceI酶切位点的质粒pEPkan-S,在细菌人工染色体重组鸭瘟病毒拯救系统平台上经两次同源重组缺失鸭瘟病毒gE基因和gI基因,首次完成了无外源碱基残留的鸭瘟病毒无痕缺失株的构建。本发明技术方案解决了缺失鸭瘟病毒基因时在缺失位点残留碱基的问题,为准确探究鸭瘟病毒基因功能及减毒活疫苗的构建提供了充分的技术支持。
附图说明
图1为pEPkan-S质粒图谱。
图2为利用Red-Based修饰技术在细菌人工染色体重组鸭瘟病毒拯救系统平台上进行基因缺失的操作流程图(以gE基因缺失为例)。
图3为CHv-BAC-G-ΔgE+ΔgI无痕缺失病毒株病毒拯救后荧光斑图片。
图4为CHv-BAC-G-ΔgE+ΔgI无痕缺失病毒株的一步生长曲线图和多步生长曲线图;其中A为一步生长曲线,B为多步生长曲线。
图5为CHv-BAC-G-ΔgE+ΔgI无痕缺失病毒株空斑形成图片。
具体实施方式
鸭瘟病毒gE和gI双基因无痕缺失株,命名为鸭瘟病毒gE和gI双缺失病毒株CHv-BAC-G-ΔgE+ΔgI,构建过程所用材料及试剂如下:
1、实验材料
(1)细胞、菌株、病毒毒株、质粒
原代鸭胚成纤维细胞由10-11日龄非免疫受精鸭胚按常规方法制备;GS1783菌株由四川农业大学实验室保存;pBAC-DPV质粒由四川农业大学实验室构建并保存;pEPkan-S质粒由四川农业大学实验室保存。
2、分子生物学试剂
质粒小提试剂盒购自TIANGEN公司;QIAGEN Plasmid Midi Kit购自QIAGEN公司;普通琼脂糖凝胶DNA回收试剂盒购自TIANGEN公司;Max DNA Polymerase购自Takara公司;TaKaRa MiniBEST Viral RNA/DNA Extraction Kit Ver.5.0购自TaKaRa公司;Lipofectamine 3000购自Invitrogen公司;即用型SABC免疫组化染色试剂盒(兔IgG)购自博士德公司;DAB显色试剂盒(黄)购自博士德公司。
3、实验所用溶液及其配制
LB液体培养基:称取Tryptone 10g、Yeast Extract 5g、氯化钠10g溶于800mL去离子水中,充分搅拌,定容至lL,高温高压灭菌。
LB固体培养基:在定容至1L的LB液体培养基中加入15g琼脂粉,高温高压灭菌后,冷却至60℃左右,加入1.5mL氯霉素(储存浓度25mg/ml)或1.5mL卡那霉素(储存浓度50mg/mL),铺制平板,待凝固后,4℃保存。
MEM:将9.6g MEM干粉和2.2g碳酸氢钠溶于800mL去离子水,充分搅拌,调节pH值至7.4,定容至lL,过滤除菌,4℃保存。
实施例1制备鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI
鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI,其构建方法包括以下步骤:
1、制备GS1783电转感受态,电转化pBAC-DPV质粒
(1)复苏带pBAC-DPV质粒的大肠杆菌于含有氯霉素的LB固体培养基中,37℃培养过夜;挑单菌落接种于含有氯霉素的LB液体培养基中,37℃培养过夜;
(2)按照QIAGEN Plasmid Midi Kit操作说明提取pBAC-DPV质粒;
(3)复苏GS1783冻存菌于LB固体培养基中,30℃培养过夜;
(4)挑取GS1783单菌落接种于5mL LB液体培养基中,30℃培养过夜,获得种子液;
(5)将5mL种子液加入100mL LB液体培养基中,30℃摇至OD600值在0.5~0.7之间;
(6)将步骤(5)所得菌液立即放入冰水混合物中冷却20min;
(7)取步骤(6)所得菌液,4℃、4500×g离心10min去上清;
(8)用预冷超纯水在冰上反复清洗步骤(7)菌体沉淀;
(9)向步骤(8)所得菌体中加入超纯水将菌液定容至500μl,每管100μl分装至预冷EP管,获得GS1783电转感受态;
(10)在100μl GS1783电转感受态中加入20ng pBAC-DPV质粒,混匀后将感受态和质粒一起加入2mm预冷的电击杯底部,15kV/cm条件下进行电击;
(11)取100μl LB液体培养基重悬电击后菌体,30℃摇菌1h后,4500×g离心菌体2min,弃上清,采用200μl LB液体培养基悬浮沉淀,涂布在含有氯霉素的LB固体培养基上,30℃培养24h,获得GS1783-pBAC-DPV菌株。
2、扩增I_SceI-Kana-gE打靶片段
(1)复苏带有pEPkan-S质粒的大肠杆菌于含有卡那霉素的LB固体培养基中,37℃培养过夜;挑单菌落接种于含有卡那霉素的LB液体培养基中,37℃培养过夜,采用质粒小提试剂盒提取pEPkan-S质粒(pEPkan-S质粒图谱见图1);
(2)以pEPkan-S质粒为模板,GS1783-BAC-ΔgE-F和GS1783-BAC-ΔgE-R为引物,扩增I_SceI-Kana-gE打靶片段,采用普通琼脂糖凝胶DNA回收试剂盒回收扩增片段;
GS1783-BAC-ΔgE-F:5’-ATACTGCCGGCCAGACTACGGAACCTCAACAATTGGTACGtagggataacagggtaatcgattt-3’(SEQ ID NO:1)
GS1783-BAC-ΔgE-R:5’-TAACTATTTCACTAGTGAGTCATTAGTTCAACATCCATGACGTACCAATTGTTGAGGTTCCGTAGTCTGGCCGGCAGTATgccagtgttacaaccaat-3’(SEQ ID NO:2)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物GS1783-BAC-ΔgE-F 1μl、下游引物GS1783-BAC-ΔgE-R 1μl、模板pEPkan-S质粒1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
利用Red-Based修饰技术在细菌人工染色体重组鸭瘟病毒拯救系统平台上进行基因缺失的操作流程图(以gE基因缺失为例)见图2,具体过程包括如下的3和4两个过程。
3、制备GS1783-pBAC-DPV电转感受态进行打靶片段打靶
(1)复苏GS1783-pBAC-DPV冻存菌于含有氯霉素的LB固体培养基中,30℃培养过夜;
(2)挑取GS1783-pBAC-DPV单菌落接种于5mL含氯霉素的LB液体培养基中,30℃培养过夜,获得种子液;
(3)将5mL种子液加入100mL含氯霉素的LB液体培养基中,置于30℃摇至OD600值在0.5~0.7之间;
(4)将步骤(3)所得菌液于42℃培养15min后立即放入冰水混合物中冷却20min;
(5)取50mL步骤(4)所得菌液,于4℃4500×g离心10min,去上清;
(6)用预冷超纯水在冰上反复清洗步骤(5)菌体沉淀;
(7)向步骤(6)所得菌体中加入超纯水将菌液定容至500μl,每管100μl分装至预冷EP管,获得GS1783-pBAC-DPV电转感受态;
(8)在100μl电转感受态中加入200ng I_SceI-Kana-gE打靶片段,混匀后将感受态和打靶片段一起加入2mm预冷的电击杯底部,15kV/cm条件下进行电击;
(9)取100μl LB液体培养基重悬电击后菌体,30℃摇菌1h后,于4500×g离心菌体2min,弃上清,200μl LB液体培养基悬浮沉淀,涂布于含有卡那霉素和氯霉素双抗生素抗性的LB固体培养基,于30℃培养48h;
(10)PCR鉴定步骤(9)所得单菌落,获得阳性菌落GS178-pBAC-DPV-gE-Kana,以步骤(9)中生长的单菌落重悬液为模板,利用扩增I_SceI-Kana-gE打靶片段上游引物GS1783-BAC-ΔgE-F和鉴定gE基因下游引物gE-R鉴定阳性菌落,获得阳性克隆子GS1783-pBAC-DPV-gE-Kana;
GS1783-BAC-ΔgE-F:5’-ATACTGCCGGCCAGACTACGGAACCTCAACAATTGGTACGtagggataacagggtaatcgattt-3’(SEQ ID NO:1)
gE-R:5’-AGCGAGTACTTCTCTGCGTC-3’(SEQ ID NO:3)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物GS1783-BAC-ΔgE-F 1μl、下游引物gE-R 1μl、模板为步骤(9)单菌落重悬液1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
4、去掉I_SceI-Kana片段
(1)挑取GS1783-pBAC-DPV-gE-Kana单菌落接种于2mL含氯霉素的LB液体培养基中,30℃培养过夜,获得种子液;
(2)取10μl步骤(1)所得种子液接种于2mL含氯霉素的LB液体培养基中,30℃培养2h至菌液呈现轻微云雾状;
(3)向步骤(2)所得菌液中加入1mL含氯霉素的LB液体培养基和5M终浓度为2%的L-阿拉伯糖,30℃培养1h;
(4)将步骤(3)所得菌液立即放入42℃水浴中培养30min;
(5)将步骤(4)所得菌液置于30℃培养2h后,取1μl菌液加入200μl LB液体培养基中混匀后涂布到含有氯霉素的LB固体培养基,30℃培养24h~48h;
(6)挑取步骤(5)中所得单菌落在含氯霉素和卡纳霉素双抗性LB固体培养基和氯霉素单抗性LB固体培养基上进行平行筛选,将氯霉素和卡纳霉素双抗性LB固体培养基不生长,氯霉素单抗性LB固体培养基生长的菌落通过PCR方法利用gE基因鉴定引物鉴定,获得阳性克隆子GS1783-pBAC-DPV-ΔgE。
gE-F:5’-TCTCAAGACGCTCTGGAATC-3’(SEQ ID NO:4)
gE-R:5’-AGCGAGTACTTCTCTGCGTC-3’(SEQ ID NO:3)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物gE-F 1μl、下游引物gE-R 1μl、模板为步骤(6)单菌落重悬液1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
5、扩增I_SceI-Kana-gI打靶片段
(1)复苏带有pEPkan-S质粒的大肠杆菌于含有卡那霉素的LB固体培养基中,37℃培养过夜;挑单菌落接种于含有卡那霉素的LB液体培养基中,37℃培养过夜,采用质粒小提试剂盒提取pEPkan-S质粒;
(2)以pEPkan-S质粒为模板,GS1783-BAC-ΔgI-F和GS1783-BAC-ΔgI-R为引物,扩增I_SceI-Kana-gI打靶片段,采用普通琼脂糖凝胶DNA回收试剂盒回收扩增片段;
GS1783-BAC-ΔgI-F:5’-GTGCGCCATATAGACGATATATTGAGTTTCAAAAATAGAAtagggataacagggtaatcgattt-3’(SEQ ID NO:5)
GS1783-BAC-ΔgI-R:5’-TCATAACAAAAACATTTACTTTTAGTCATACTGATGTGAATTCTATTTTTGAAACTCAATATATCGTCTATATGGCGCACgccagtgttacaaccaat-3’(SEQ ID NO:6)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物GS1783-BAC-ΔgI-F 1μl、下游引物GS1783-BAC-ΔgI-R 1μl、模板pEPkan-S质粒1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
6、制备GS1783-pBAC-DPV-ΔgE电转感受态进行打靶片段打靶
(1)复苏GS1783-pBAC-DPV-ΔgE冻存菌于含有氯霉素的LB固体培养基中,30℃培养过夜;
(2)挑取GS1783-pBAC-DPV-ΔgE单菌落接种于5mL含氯霉素的LB液体培养基中,30℃培养过夜,获得种子液;
(3)将5mL种子液加入100mL含氯霉素的LB液体培养基中,置于30℃摇至OD600值在0.5~0.7之间;
(4)将步骤(3)所得菌液于42℃培养15min后立即放入冰水混合物中冷却20min;
(5)取50mL步骤(4)所得菌液,于4℃4500×g离心10min,去上清;
(6)用预冷超纯水在冰上反复清洗步骤(5)菌体沉淀;
(7)向步骤(6)所得菌体中加入超纯水将菌液定容至500μl,每管100μl分装至预冷EP管,获得GS1783-pBAC-DPV-ΔgE电转感受态;
(8)在100μl电转感受态中加入200ng I_SceI-Kana-gI打靶片段,混匀后将感受态和打靶片段一起加入2mm预冷的电击杯底部,15kV/cm条件下进行电击;
(9)取100μl LB液体培养基重悬电击后菌体,30℃摇菌1h后,于4500×g离心菌体2min,弃上清,200μl LB液体培养基悬浮沉淀,涂布于含有卡那霉素和氯霉素双抗生素抗性的LB固体培养基,于30℃培养48h;
(10)PCR鉴定步骤(9)所得单菌落,获得阳性菌落GS178-pBAC-DPV-ΔgE-gI-Kana,以步骤(9)中生长的单菌落重悬液为模板,利用扩增I_SceI-Kana-gI打靶片段上游引物GS1783-BAC-ΔgI-F和鉴定gE基因下游引物gI-R鉴定阳性菌落;
GS1783-BAC-ΔgI-F:5’-GTGCGCCATATAGACGATATATTGAGTTTCAAAAATAGAAtagggataacagggtaatcgattt-3(SEQ ID NO:5)
gI-R:5’-GACCGGTAGTTCCAATCACT-3’(SEQ ID NO:7)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物GS1783-BAC-ΔgI-F 1μl、下游引物gI-R 1μl、模板1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
7、去掉I_SceI-Kana片段
(1)挑取GS1783-pBAC-DPV-ΔgE-gI-Kana单菌落接种于2mL含氯霉素的LB液体培养基中,30℃培养过夜,获得种子液;
(2)取10μl步骤(1)所得种子液接种于2mL含氯霉素的LB液体培养基中,30℃培养2h至菌液呈现轻微云雾状;
(3)向步骤(2)所得菌液中加入1mL含氯霉素的LB液体培养基和5M终浓度为2%的L-阿拉伯糖,30℃培养1h;
(4)将步骤(3)所得菌液立即放入42℃水浴中培养30min;
(5)将步骤(4)所得菌液置于30℃培养2h后,取1μl菌液加入200μl LB液体培养基中混匀后涂布到含有氯霉素的LB固体培养基,30℃培养24h~48h;
(6)挑取步骤(5)中所得单菌落在含氯霉素和卡纳霉素双抗性LB固体培养基和氯霉素单抗性LB固体培养基上进行平行筛选,将氯霉素和卡纳霉素双抗性LB固体培养基不生长,氯霉素单抗性LB固体培养基生长的菌落通过PCR方法利用gI基因上游鉴定引物gI-F和gI基因下游鉴定引物gE-R进行鉴定,获得阳性克隆子GS1783-pBAC-DPV-ΔgE+ΔgI。
gI-F:5’-TGTGGGTGGGTCATCTACAT-3’(SEQ ID NO:8)
gE-R:5’-AGCGAGTACTTCTCTGCGTC-3’(SEQ ID NO:3)
PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物gE-F 1μl、下游引物gE-R 1μl、模板为步骤(6)单菌落重悬液1μl;
PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min,于16℃保存。
8、拯救病毒
(1)复苏GS1783-pBAC-DPV-ΔgE+ΔgI冻存菌于含有氯霉素的LB固体培养基中,30℃培养过夜;
(2)按照QIAGEN Plasmid Midi Kit操作说明提取pBAC-DPV-ΔgE+ΔgI质粒;
(3)制备鸭胚成纤维细胞(DEF)并接种于12孔板,37℃,5%CO2培养24h后,按照Lipofectamine 3000操作说明转染pBAC-DPV-ΔgE+ΔgI质粒,96h后观察荧光斑,收集病毒,反复冻融三次后接种于长满DEF的6空斑,96h后观察荧光斑,获得gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI(见图3)。
实施例2无痕缺失株CHv-BAC-G-ΔgE+ΔgI生长曲线的测定
1、一步生长曲线的测定
将亲本病毒DPV CHv-BAC-G和gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI分别以2MOI接种DEF细胞,接毒后6h、12h、18h、24h收集上清和细胞,每个时间点做三次重复。待收集完全后,反复冻融2次,于96孔板检测病毒滴度,一步生长曲线如图4A所示。结果表明gE和gI基因的缺失不会显著影响DPV CHv病毒的复制。
2、多步生长曲线的测定
将亲本病毒DPV CHv-BAC-G和gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI分别以0.01MOI接种DEF细胞,接毒后12h、24h、48h、72h收集上清和细胞,每个时间点做三次重复。待收集完全后,反复冻融2次,于96孔板检测病毒滴度,多步生长曲线如图4B所示。结果表明gE和gI基因的缺失不会显著影响DPV CHv病毒的增殖情况。
实施例3无痕缺失株CHv-BAC-G-ΔgE+ΔgI空斑形成实验
将亲本病毒DPV CHv-BAC-G和gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI分别以0.01MOI接种布满DEF细胞的6孔板,37℃、5%CO2吸附2h后,去上清,加入2mL1%甲基纤维素,37℃、5%CO2培养48h后,去1%甲基纤维素,PBS洗涤3次,4%多聚甲醛4℃固定过夜,PBS洗涤3次,加入H2O2和甲醇以体积比为1:50混合的混合液,室温孵育30min,蒸馏水洗涤3次,加入5%BSA封闭液,室温孵育30min,加入兔抗DPV,4℃孵育过夜,PBS洗涤3次,加入生物素化山羊抗兔IgG,37℃孵育30min,PBS洗涤3次,滴加SABC底物,37℃孵育30min,PBS洗涤3次,DAB显色液避光显色,封片。空斑形成实验结果如图5所示。结果表明gE和gI基因的缺失可能影响DPV CHv病毒在细胞内增殖及传播情况。
此外,本发明还对鸭瘟病毒gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI做了遗传稳定性实验。
遗传稳定性:鸭瘟病毒gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI在DEF细胞上传代20代,均出现蚀斑,表明所获得的鸭瘟病毒gE、gI基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI在DEF中稳定遗传。
序列表
<110> 四川农业大学
<120> 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 64
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atactgccgg ccagactacg gaacctcaac aattggtacg tagggataac agggtaatcg 60
attt 64
<210> 2
<211> 98
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
taactatttc actagtgagt cattagttca acatccatga cgtaccaatt gttgaggttc 60
cgtagtctgg ccggcagtat gccagtgtta caaccaat 98
<210> 3
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
agcgagtact tctctgcgtc 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
tctcaagacg ctctggaatc 20
<210> 5
<211> 64
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
gtgcgccata tagacgatat attgagtttc aaaaatagaa tagggataac agggtaatcg 60
attt 64
<210> 6
<211> 98
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
tcataacaaa aacatttact tttagtcata ctgatgtgaa ttctattttt gaaactcaat 60
atatcgtcta tatggcgcac gccagtgtta caaccaat 98
<210> 7
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
gaccggtagt tccaatcact 20
<210> 8
<211> 98
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
ttattaatct caggagcctg tgtagcgttt ataggaagta gtgttctgtc atgatgcctg 60
caagcggtaa cgaaaacgat tgttacaacc aattaacc 98
Claims (6)
1.鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI,于2018年7月4日保藏于中国典型培养物保藏中心,保藏编号为CCTCC NO:V201827。
2.如权利要求1所述的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI的构建方法,其特征在于,包括以下步骤:
(1)将pBAC-DPV质粒转化到GS1783大肠杆菌感受态中,获得GS1783-pBAC-DPV菌株,然后制备GS1783-pBAC-DPV感受态;
(2)以pEPkan-S为模板,以GS1783-BAC-ΔgE-F和GS1783-BAC-ΔgE-R作为引物,通过PCR方法扩增包含I_SceI酶切位点和Kana元件的碱基片段以及gE基因上游和下游各40bp同源臂的打靶片段I_SceI-Kana-gE,切胶回收获得I_SceI-Kana-gE片段;
(3)将I_SceI-Kana-gE片段转化到GS1783-pBAC-DPV感受态中,筛选,获得阳性克隆子GS1783-pBAC-DPV-gE-Kana;
(4)将阳性克隆子GS1783-pBAC-DPV-gE-Kana中的I_SceI-Kana片段去掉,制备GS1783-pBAC-DPV-ΔgE感受态;
(5)以pEPkan-S为模板,以GS1783-BAC-ΔgI-F和GS1783-BAC-ΔgI-R作为引物,通过PCR方法扩增包含I_SceI酶切位点和Kana元件的碱基片段以及gI基因上游和下游各40bp同源臂的打靶片段I_SceI-Kana-gI,切胶回收获得I_SceI-Kana-gI片段;
(6)将I_SceI-Kana-gI片段转化到GS1783-pBAC-DPV-ΔgE感受态中,经抗生素筛选和PCR鉴定,获得阳性克隆子GS1783-pBAC-DPV-ΔgE-gI-Kana;
(7)将阳性克隆子GS1783-pBAC-DPV-ΔgE-gI-Kana中的I_SceI-Kana片段去掉,制备阳性克隆子GS1783-pBAC-DPV-ΔgE+ΔgI;
(8)从阳性克隆子GS1783-pBAC-DPV-ΔgE+ΔgI中提取pBAC-DPV-ΔgE+ΔgI质粒,将pBAC-DPV-ΔgE+ΔgI质粒转染DEF细胞,通过克隆筛选,获得gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI。
3.根据权利要求2所述的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI的构建方法,其特征在于,步骤(2)和步骤(5)中PCR扩增体系为:ddH2O 22μl、Max DNA Polymerase 25μl、上游引物1μl、下游引物1μl、模板1μl。
4.根据权利要求2所述的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI的构建方法,其特征在于,步骤(2)和步骤(5)中PCR扩增条件为:98℃预变性2min、98℃变性10s、55℃退火15s、72℃延伸5s,共30个循环,最后72℃延伸10min。
5.根据权利要求2-4任一项所述的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI的构建方法,其特征在于,步骤(2)中引物序列为:
GS1783-BAC-ΔgE-F:5’-ATACTGCCGGCCAGACTACGGAACCTCAACAATTGGTACGtagggataacagggtaatcgattt-3’;
GS1783-BAC-ΔgE-R:5’-TAACTATTTCACTAGTGAGTCATTAGTTCAACATCCATGACGTACCAATTGTTGAGGTTCCGTAGTCTGGCCGGCAGTATgccagtgttacaaccaat-3’。
6.根据权利要求2-4任一项所述的鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI的构建方法,其特征在于,步骤(5)中引物序列为:
GS1783-BAC-ΔgI-F:5’-GTGCGCCATATAGACGATATATTGAGTTTCAAAAATAGAAtagggataacagggtaatcgattt-3’;
GS1783-BAC-ΔgI-R:5’-TCATAACAAAAACATTTACTTTTAGTCATACTGATGTGAATTCTATTTTTGAAACTCAATATATCGTCTATATGGCGCACgccagtgttacaaccaat-3’。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811600142.6A CN109628417A (zh) | 2018-12-26 | 2018-12-26 | 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811600142.6A CN109628417A (zh) | 2018-12-26 | 2018-12-26 | 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109628417A true CN109628417A (zh) | 2019-04-16 |
Family
ID=66077757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811600142.6A Pending CN109628417A (zh) | 2018-12-26 | 2018-12-26 | 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109628417A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135108A1 (zh) * | 2018-12-26 | 2020-07-02 | 四川农业大学 | 鸭瘟病毒gE和gI双基因无痕缺失株DPV CHv-ΔgE+ΔgI及其构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102994534A (zh) * | 2012-05-08 | 2013-03-27 | 四川农业大学 | 鸭瘟病毒gE基因转移载体pUC-ΔgE-EGFP及重组株DPV-ΔgE-EGFP |
CN105802922A (zh) * | 2016-04-19 | 2016-07-27 | 四川农业大学 | 一种细菌人工染色体重组鸭瘟病毒拯救系统平台的构建方法及应用 |
-
2018
- 2018-12-26 CN CN201811600142.6A patent/CN109628417A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102994534A (zh) * | 2012-05-08 | 2013-03-27 | 四川农业大学 | 鸭瘟病毒gE基因转移载体pUC-ΔgE-EGFP及重组株DPV-ΔgE-EGFP |
CN105802922A (zh) * | 2016-04-19 | 2016-07-27 | 四川农业大学 | 一种细菌人工染色体重组鸭瘟病毒拯救系统平台的构建方法及应用 |
Non-Patent Citations (2)
Title |
---|
孙昆峰: "鸭瘟病毒gC基因疫苗在鸭体内分布规律及gC、gE基因缺失株的构建和生物学特性的初步研究", 《中国博士学位论文全文数据库(电子期刊)农业科技辑》 * |
陈柳等: "DEV囊膜糖蛋白gI基因缺失病毒生物学特性研究", 《浙江畜牧兽医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020135108A1 (zh) * | 2018-12-26 | 2020-07-02 | 四川农业大学 | 鸭瘟病毒gE和gI双基因无痕缺失株DPV CHv-ΔgE+ΔgI及其构建方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109536463A (zh) | 鸭瘟病毒gE和gI双基因无痕缺失株DPV CHv-ΔgE+ΔgI及其构建方法 | |
CN105400784B (zh) | 一种枯草芽孢杆菌诱导性强启动子及其应用 | |
CN110295183A (zh) | 一种基于CsPrx25超量表达提高柑橘对溃疡病抗性的方法 | |
CN109576295A (zh) | 一种鸭瘟病毒去MiniF元件gC基因缺失株DPV CHv-ΔgC及其构建方法 | |
CN106987559A (zh) | 一种重组chok1细胞株的构建方法及其应用 | |
CN115058449A (zh) | 一种利用CsWRKY43干扰以提高柑橘溃疡病抗性的方法 | |
CN109628417A (zh) | 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 | |
CN114196556A (zh) | 一种高毒力蝗绿僵菌菌株及其构建方法 | |
CN109576293A (zh) | 鸭瘟病毒gE基因ET区域无痕缺失株CHv-BAC-G-gEΔET及其构建方法 | |
CN109486773A (zh) | 鸭瘟病毒gE基因CT区域无痕缺失株CHv-BAC-G-gEΔCT及其构建方法 | |
CN109593731A (zh) | 鸭瘟病毒gI基因无痕缺失株CHv-BAC-G-ΔgI及其构建方法 | |
CN109576294A (zh) | 鸭瘟病毒gE基因无痕缺失株CHv-BAC-G-ΔgE及其构建方法 | |
CN109593730A (zh) | 鸭瘟病毒Lorf5基因无痕缺失株DPV CHv-ΔLorf5及其构建方法 | |
CN109182153B (zh) | 一种高毒力蝗绿僵菌工程菌株及其构建方法 | |
CN109609548A (zh) | 鸭瘟病毒gI基因无痕缺失株DPV CHv-ΔgI及其构建方法 | |
CN109486774A (zh) | 鸭瘟病毒gE基因CT区域无痕缺失株DPV CHv-gEΔCT及其构建方法 | |
CN109486772A (zh) | 鸭瘟病毒gE基因ET区域无痕缺失株DPV CHv-gEΔET及其构建方法 | |
CN109593732A (zh) | 鸭瘟病毒gE基因无痕缺失株DPV CHv-ΔgE及其构建方法 | |
CN109609549A (zh) | 一种鸭瘟病毒UL41基因无痕缺失株CHv-BAC-G-ΔUL41及其构建方法 | |
CN109609547A (zh) | 鸭瘟病毒Lorf5基因无痕缺失株CHv-BAC-G-ΔLorf5及其构建方法 | |
CN106243199B (zh) | 对甜菜夜蛾具有高活性的Vip3Aa11蛋白突变体 | |
CN109609550A (zh) | 一种鸭瘟病毒UL41基因无痕缺失株DPV CHv-ΔUL41及其构建方法 | |
CN108754616B (zh) | 伪狂犬病病毒基因组Fosmid文库、构建方法及其在构建突变体中的应用 | |
CN107663523A (zh) | 一种优化的鸡α干扰素基因真核表达重组质粒及其制备方法与应用 | |
CN108754019B (zh) | 一种猪流行性腹泻病毒orf1基因全序列的扩增方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |
|
RJ01 | Rejection of invention patent application after publication |